Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMOOTH Study: Switching from reference etanercept maintenance dose to optimal biosimilar dose in RA patients with economic issues
jRCTs031210471Completed
- Sponsor
- AYUMI Pharmaceutical Corporation
- Start
- Feb 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of etanercept in rheumatoid arthritis (RA), sponsored by AYUMI Pharmaceutical Corporation. Started Feb 2022; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCTs031210471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210471.